4D Molecular Therapeutics (FDMT) Other Non Operating Income (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Other Non Operating Income of -$4000.0 for Q1 2026, down 105.97% year-over-year from $67000.0 in Q1 2025, and up 81.82% quarter-over-quarter from -$22000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Other Non Operating Income (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Other Non Operating Income for 7 consecutive years, with -$4000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 105.97% year-over-year to -$4000.0; the TTM figure through Mar 2026 stood at -$108000.0 (changed N/A YoY), while the FY2025 annual figure was -$37000.0, up 51.95% from the prior year.
- Other Non Operating Income improved to -$4000.0 in Q1 2026 per FDMT's latest filing, from -$22000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $67000.0 in Q1 2025 and bottomed at -$158000.0 in Q3 2023.
- Historically, Other Non Operating Income has averaged -$20750.0 across 5 years, with a median of -$15000.0 in 2023.
- On a YoY basis, Other Non Operating Income climbed as much as 770.0% in 2025 and fell as far as 2000.0% in 2025.
- 4D Molecular Therapeutics' Other Non Operating Income stood at $3000.0 in 2022, then plunged by 466.67% to -$11000.0 in 2023, then sank by 90.91% to -$21000.0 in 2024, then slipped by 4.76% to -$22000.0 in 2025, then jumped by 81.82% to -$4000.0 in 2026.
- Business Quant data shows FDMT's Other Non Operating Income at -$4000.0 in Q1 2026, -$22000.0 in Q4 2025, and -$21000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -166,000.00 |
| Mar 31, 2026 | -4,000.00 |
| Dec 31, 2025 | -22,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -61,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -45,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | -11,000.00 |
| Sep 30, 2023 | -158,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | -19,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Sep 30, 2022 | 9,000.00 |
| Mar 31, 2022 | -46,000.00 |
| Dec 31, 2021 | -7,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Mar 31, 2021 | -101,000.00 |